Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

231
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
231
Drug Regulation01:25

Drug Regulation

1.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

668
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
668
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.4K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.4K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

835
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
835

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Which surfactant is cost-effective in Neonatal Respiratory Distress Syndrome?

Cost effectiveness and resource allocation : C/E·2026
Same author

Resilience in Urban Pharmacies: A Mixed-Methods Model for Performance and Patient Satisfaction During Crises.

Iranian journal of pharmaceutical research : IJPR·2026
Same author

Estimation of direct and indirect costs associated with obesity treatment interventions among adult populations in Iran.

BMC health services research·2026
Same author

Development and Assessment of a Decentralization Framework in Iran Pharmaceutical Regulatory Systems Based on Good Governance Indicators.

Iranian journal of pharmaceutical research : IJPR·2025
Same author

Cost-Utility Analysis of Mirabegron Compared to Solifenacin in the Treatment of Overactive Bladder (OAB) in Iran.

Iranian journal of pharmaceutical research : IJPR·2025
Same author

Developing a Discrete Choice Experiment Instrument for Evaluating Patients' Preferences in Precision Oncology.

Iranian journal of pharmaceutical research : IJPR·2025

Related Experiment Video

Updated: Aug 29, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?

Nikta Shobeiri1, Farzad Peiravian1, Nazila Yousefi1

  • 1Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Iranian Journal of Pharmaceutical Research : IJPR
|September 5, 2022
PubMed
Summary

Managed entry agreements (MEAs) in Iran prioritize patient access and budget impact. Stakeholder insights reveal strengths like early access and opportunities for resource allocation, but weaknesses and threats require careful management for successful implementation.

Keywords:
IranManaged Entry AgreementsPharmaceuticalsSWOTUncertainties

More Related Videos

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.1K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.0K

Related Experiment Videos

Last Updated: Aug 29, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.1K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.0K

Area of Science:

  • Health economics
  • Pharmaceutical policy
  • Market access

Background:

  • Uncertainty in real-world product profiles hinders pharmaceutical market access.
  • Managed entry agreements (MEAs) are formal arrangements to manage these uncertainties.
  • Developing countries have minimal experience with MEAs, unlike developed nations.

Purpose of the Study:

  • To explore stakeholders' insights on implementing MEAs in Iran.
  • To identify objectives and priorities for MEA implementation.
  • To facilitate optimal policy execution by addressing the experience gap.

Main Methods:

  • Three-phase research approach: focus group interviews, Analytic Hierarchy Process (AHP), and SWOT analysis.
  • Focus groups identified MEA objectives in Iran.
  • AHP prioritized uncertainties, while SWOT analysis assessed MEA strengths, weaknesses, opportunities, and threats.

Main Results:

  • Stakeholders prioritize MEAs for improved patient access to innovative drugs and managing budget impact uncertainty.
  • SWOT analysis indicates MEAs offer strengths (early access, efficient resource allocation) and opportunities (post-marketing studies).
  • Key weaknesses and threats include defining outcomes, high transaction costs, and inadequate infrastructure.

Conclusions:

  • Successful MEA implementation in Iran hinges on addressing identified weaknesses and threats.
  • Considering stakeholder perspectives is crucial for effective MEA execution.
  • Constructive interaction among all stakeholders is essential for adequate MEA performance.